Combination strategies to enhance antitumor ADCC

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Monoclonal antibodies are key cancer therapeutics, relying on immune cell engagement for efficacy.
• Antibody-dependent cell-mediated cytotoxicity (ADCC) is a critical mechanism where immune cells eliminate antibody-targeted tumor cells.

Purpose of the Study:

• To review strategies for enhancing ADCC in cancer immunotherapy.
• To discuss the biologic rationale and clinical outcomes of augmenting antibody-mediated antitumor immunity.

Main Methods:

• Review of existing literature on ADCC enhancement strategies.
• Analysis of approaches targeting NK cells, γδ T cells, macrophages, and dendritic cells.
• Categorization of strategies based on increasing target-monoclonal antibody-effector binding, triggering activating signals, or blocking inhibitory signals.

Main Results:

• Combination strategies offer broad applicability across existing antibodies and diseases.
• Regulatory feasibility is enhanced by combining with approved agents.
• Proven efficacy of the antitumor antibody component provides assurance to clinicians and patients.

Conclusions:

• Enhancing ADCC through various immunotherapeutic strategies can significantly improve antitumor activity.
• Targeting innate immune cells and modulating effector cell signals are promising avenues for cancer treatment.
• Combination therapies represent a feasible and effective approach to augment monoclonal antibody efficacy in oncology.